ATOS
NASDAQAtossa Therapeutics Inc.
Price$4.39-0.19 (-4.15%)
01:45 PM07:45 PM
News · 26 weeks43-83%
2025-12-142026-06-07
Mix2490d
- SEC Filings8(33%)
- Insider8(33%)
- Other7(29%)
- Leadership1(4%)
Latest news
25 items- PRAtossa Therapeutics Announces ASCO 2026 Abstracts Highlighting (Z)-Endoxifen Activity Across ESR1 Mutations and Ongoing EVANGELINE Phase 2 TrialPreclinical Data Abstract Demonstrates Robust Estrogen Receptor (ER) Inhibition in ESR1-Mutant Breast Cancer Models at Clinically Relevant ConcentrationsTrial-in-Progress Abstract Details Ongoing Phase 2 EVANGELINE Study of (Z)-Endoxifen Plus Goserelin as Neoadjuvant Therapy in Premenopausal Women With ER+/HER2- Breast CancerSEATTLE, May 27, 2026 /PRNewswire/ -- Atossa Therapeutics, Inc. (NASDAQ:ATOS) ("Atossa" or the "Company"), a clinical-stage biopharmaceutical company developing novel therapies in oncology and other areas of significant unmet medical need, today announced that two abstracts featuring (Z)-endoxifen have been accepted for presentation at the 2026 American Society of Clinic
- PRAtossa Therapeutics Announces Acceptance of Manuscript Highlighting Utrophin-Modulation Potential of (Z)-Endoxifen in Duchenne Muscular DystrophyReview article accepted for publication in Degenerative Neurological and Neuromuscular Disease and builds on Atossa's previously published Duchenne Muscular Dystrophy (DMD) researchSEATTLE, May 20, 2026 /PRNewswire/ -- Atossa Therapeutics, Inc. (NASDAQ:ATOS) (Atossa or the Company), a clinical-stage biopharmaceutical company developing novel therapies in oncology and other areas of significant unmet clinical need, today announced that the manuscript titled, "(Z)-Endoxifen as a Potential Modulator of Utrophin Pathways in Duchenne Muscular Dystrophy: A Mechanistic and Transcriptomic Perspective," has been accepted for publication in Degenerative Neurological and Neuromuscular Disease.
- INSIDERDirector Steinhart Richard I was granted 10,000 shares (SEC Form 4)4 - ATOSSA THERAPEUTICS, INC. (0001488039) (Issuer)
- INSIDERDirector Chen Shu-Chih was granted 10,000 shares (SEC Form 4)4 - ATOSSA THERAPEUTICS, INC. (0001488039) (Issuer)
- INSIDERDirector Remmel H. Lawrence was granted 10,000 shares, increasing direct ownership by 1,464% to 10,683 units (SEC Form 4)4 - ATOSSA THERAPEUTICS, INC. (0001488039) (Issuer)
- INSIDERDirector Finn Jonathan was granted 10,000 shares, increasing direct ownership by 600% to 11,666 units (SEC Form 4)4 - ATOSSA THERAPEUTICS, INC. (0001488039) (Issuer)
- INSIDERDirector Galli Stephen J was granted 10,000 shares, increasing direct ownership by 166,667% to 10,006 units (SEC Form 4)4 - ATOSSA THERAPEUTICS, INC. (0001488039) (Issuer)
- INSIDERDirector Cigler Tessa was granted 10,000 shares (SEC Form 4)4 - ATOSSA THERAPEUTICS, INC. (0001488039) (Issuer)
- PRAtossa Therapeutics to Host Virtual KOL Event Featuring Dr. Laura Esserman to Discuss Development of (Z)-Endoxifen in ER-Positive Breast CancerEvent to feature Dr. Laura Esserman, internationally recognized surgical oncologist, breast cancer expert, and founder and principal investigator of the I-SPY TrialsSEATTLE, May 14, 2026 /PRNewswire/ -- Atossa Therapeutics, Inc. (NASDAQ:ATOS) ("Atossa" or the "Company"), a clinical-stage biopharmaceutical company developing novel therapies in oncology and other areas of significant unmet medical need, today announced that it will host a virtual key opinion leader event focused on the evolving clinical and translational data supporting the development of (Z)-endoxifen, the Company's investigational selective estrogen receptor modulator/degrader, or SERM/D, as a potential next-generation endoc
- SECAtossa Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - ATOSSA THERAPEUTICS, INC. (0001488039) (Filer)
- PRAtossa Therapeutics Reports First Quarter 2026 Financial Results and Provides a Corporate UpdateSEATTLE, May 8, 2026 /PRNewswire/ -- Atossa Therapeutics, Inc. (NASDAQ:ATOS) (Atossa or the Company), a clinical-stage biopharmaceutical company developing novel therapies in oncology and other areas of high unmet clinical need, today announces its financial results and provides an update on recent corporate developments for the first quarter ended March 31, 2026. "During the quarter, we made meaningful progress advancing our (Z)-endoxifen development strategy across both oncology and rare disease indications," stated Dr. Steven Quay, M.D., Ph.D., Atossa Therapeutics' President
- SECSEC Form 10-Q filed by Atossa Therapeutics Inc.10-Q - ATOSSA THERAPEUTICS, INC. (0001488039) (Filer)
- SECAtossa Therapeutics Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders8-K - ATOSSA THERAPEUTICS, INC. (0001488039) (Filer)
- PRAtossa Therapeutics Receives FDA Rare Pediatric Disease Designation for (Z)-Endoxifen for McCune-Albright SyndromeDesignation expands (Z)-endoxifen program into rare pediatric endocrine disorder and qualifies Atossa for a Priority Review Voucher award upon approvalSEATTLE, May 4, 2026 /PRNewswire/ -- Atossa Therapeutics, Inc. (NASDAQ:ATOS) ("Atossa" or the "Company"), a clinical-stage biopharmaceutical company developing novel therapies in oncology and other areas of high unmet clinical need, today announced that the U.S. Food and Drug Administration ("FDA") has granted Rare Pediatric Disease ("RPD") designation to (Z)-endoxifen for the treatment of McCune-Albright Syndrome ("MAS") in females.
- SECSEC Form 8-K filed by Atossa Therapeutics Inc.8-K - ATOSSA THERAPEUTICS, INC. (0001488039) (Filer)
- INSIDERSEC Form 4 filed by Quay Steven C4 - ATOSSA THERAPEUTICS, INC. (0001488039) (Issuer)
- INSIDERSEC Form 4 filed by Daniel Mark James4 - ATOSSA THERAPEUTICS, INC. (0001488039) (Issuer)
- SECSEC Form DEF 14A filed by Atossa Therapeutics Inc.DEF 14A - ATOSSA THERAPEUTICS, INC. (0001488039) (Filer)
- PRAtossa Therapeutics Reports Fourth Quarter and Year-End 2025 Financial Results and Provides a Corporate UpdateSEATTLE, March 25, 2026 /PRNewswire/ -- Atossa Therapeutics, Inc. (NASDAQ:ATOS) (Atossa or the Company), a clinical-stage biopharmaceutical company developing novel therapies in oncology and other areas of high unmet clinical need, today announces its financial results for the fourth quarter and year ended December 31, 2025 and provides an update on recent corporate developments. "While we have consistently made meaningful and measurable progress across our (Z)-endoxifen development strategy in oncology over the last 12 months, we continue to explore the best opportunities to le
- SECSEC Form 10-K filed by Atossa Therapeutics Inc.10-K - ATOSSA THERAPEUTICS, INC. (0001488039) (Filer)
- SECAtossa Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - ATOSSA THERAPEUTICS, INC. (0001488039) (Filer)
- SECSEC Form PRE 14A filed by Atossa Therapeutics Inc.PRE 14A - ATOSSA THERAPEUTICS, INC. (0001488039) (Filer)
- PRThe Patent Cliff is Coming, Driving Smart Money Towards Precision OncologyVANCOUVER, British Columbia, March 19, 2026 (GLOBE NEWSWIRE) -- Equity-Insider.com News Commentary — Big money is moving back into biotech. Institutional investors have been writing some of the largest checks in years, with major financing rounds already closing in the first months of 2026[1], a sign that capital is rotating toward clinical-stage companies with validated science. That capital is not spreading evenly: it is concentrating on precision medicine, where the global oncology precision medicine market is projected to reach $303 billion by 2035[2], growing at approximately 9% annually as targeted cancer treatments move from promising idea to standard care. The five companies in thi
- PRAtossa Therapeutics Strengthens Clinical Leadership Team with the Addition of Two Experienced Biopharma ExecutivesKathy Puyana Theall, M.D. and Adebola Giwa, M.D. bring deep expertise across oncology, rare diseases, and global clinical development to support advancement of Atossa's pipelineSEATTLE, March 19, 2026 /PRNewswire/ -- Atossa Therapeutics, Inc. (NASDAQ:ATOS) ("Atossa" or the "Company"), a clinical-stage biopharmaceutical company developing novel therapies in oncology and other rare diseases, today announces the engagement of Kathy Puyana Theall, M.D., as Medical Director - Breast Oncology, and Adebola Giwa, M.D., as Medical Director - Rare Diseases. The addition of these two highly experienced physicians and clinical leaders meaningfully strengthens Atossa's ability to execute on its (Z)-endo
- PRAtossa Therapeutics Presents Clinical Trial Update Highlighting (Z)-Endoxifen Research at the 2026 MDA Clinical & Scientific ConferenceStudy Highlights Findings that (Z)-endoxifen Restores Muscle Performance and Lowers Damage Biomarkers in mdx5Cv Dystrophic MiceSEATTLE, March 12, 2026 /PRNewswire/ -- Atossa Therapeutics, Inc. (NASDAQ:ATOS) ("Atossa" or the "Company"), a clinical-stage biopharmaceutical company developing novel therapies in oncology and other rare disease indications with significant unmet need, presented an oral clinical trial update on (Z)-endoxifen at the MDA Clinical & Scientific Conference on March 11, 2026, in Orlando, FL. Presentation HighlightsThe mdx5Cv Dystrophic mouse model, a trusted
ATOS FAQ
6 questionsWhat does Atossa Therapeutics Inc. do?
Atossa Therapeutics, Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines in the areas of oncology and infectious diseases. The company's lead program is Endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer. It is also developing AT-301, a proprietary drug candidate for nasal administration in patients diagnosed with COVID-19; AT-H201, a drug candidate to improve lung function in COVID-19 patients; and immunotherapy/chimeric antigen receptor therapy programs for the treatment of breast cancer...Where does ATOS stock trade?
Atossa Therapeutics Inc. (ATOS) is listed on NASDAQ.What sector and industry is ATOS in?
Atossa Therapeutics Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Atossa Therapeutics Inc. go public?
Atossa Therapeutics Inc. (ATOS) completed its IPO in 2012.What companies are similar to ATOS?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), AZN (AstraZeneca PLC), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.). Compare ATOS side-by-side with any of them on Quantisnow.How can I track ATOS on Quantisnow?
Quantisnow aggregates Atossa Therapeutics Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow ATOS to receive live email and push alerts on every new disclosure.